Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kamada Ltd (IL:KMDA)
:KMDA
KMDA Stock Chart & Stats
Day’s Range― - ―
52-Week Range1,795.00 - 3,045.00
Previous CloseN/A
Volume698.59K
Average Volume (3M)N/A
Market Cap
1.57B
Enterprise Value922.83M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)26.7
Beta0.44
Next Earnings
May 20, 2025EPS Estimate
0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.02
Shares Outstanding57,485,615
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit16.63
Enterprise Value/Ebitda32.68
Forecast
1Y Price Target
3,923.19Price Target Upside43.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Kamada News
PremiumCompany Announcements
Kamada Projects Double-Digit Growth for 2025, Expands Plasma Operations
PremiumCompany Announcements
Kamada Ltd. Approves Board Re-Elections and Auditor Appointment---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceKamada affirms their strong financial position for 2024 and 2025 with a projected increase in revenue and adjusted EBITDA.
Growth StrategyKamada's focus for 2025 is on securing new business development and M&A transactions, which could be a growth driver.
Regulatory ApprovalFDA agrees to previously proposed increased alpha value for the Phase 3 InnovAATe trial, which may decrease the required sample size and accelerate enrollment.
Bears Say
Partnership ChallengesDespite prior positive guidance from the European Medicines Agency, Kamada has yet to find a partner for the AAT program.
Partnership DelaysIt is concerning that a partnership has not yet materialized for the AAT program.
Trial Enrollment ChallengesEnrollment in the AAT trial is expected to be a challenge despite additional sites being opened.
---
KMDA FAQ
What was Kamada Ltd’s price range in the past 12 months?
Kamada Ltd lowest stock price was 1795.00 and its highest was 3045.00 in the past 12 months.
What is Kamada Ltd’s market cap?
Kamada Ltd’s market cap is 1.57B.
When is Kamada Ltd’s upcoming earnings report date?
Kamada Ltd’s upcoming earnings report date is May 20, 2025 which is in 86 days.
How were Kamada Ltd’s earnings last quarter?
Currently, no data Available
Is Kamada Ltd overvalued?
According to Wall Street analysts Kamada Ltd’s price is currently Undervalued.
Does Kamada Ltd pay dividends?
Kamada Ltd does not currently pay dividends.
What is Kamada Ltd’s EPS estimate?
Kamada Ltd’s EPS estimate is 0.19.
How many shares outstanding does Kamada Ltd have?
Kamada Ltd has 57,485,615 shares outstanding.
What happened to Kamada Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kamada Ltd?
Among the largest hedge funds holding Kamada Ltd’s share is ARK Investment Management LLC. It holds Kamada Ltd’s shares valued at 0.
---
Kamada Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
3,923.19 (43.76% Upside)
3,923.19 (43.76% Upside)
Blogger Sentiment
Bullish
IL:KMDA Sentiment 70%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.12%
12-Months-Change
Fundamentals
Return on Equity
6.37%
Trailing 12-Months
Asset Growth
4.20%
Trailing 12-Months
Company Description
Kamada Ltd
Kamada Ltd. engages in the development and production of pharmaceutical products. It operates through the Proprietary Products segment and the Distribution segment. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the supply of plasma-based products for clinical use. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.
---
KMDA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong financial performance with significant revenue and EBITDA growth. The company showcased robust cash flow and strategic expansions in plasma collection and biosimilar products. However, there are ongoing challenges with FDA discussions and increased operating expenses. Overall, the highlights significantly outweigh the lowlights, indicating positive momentum.Read More>---
KMDA Stock 12 Month Forecast
Average Price Target
3,923.19
▲(43.76% Upside)
Technical Analysis
Best Analysts Covering KMDA
1 Year
1 Year Success Rate
8/10 ratings generated profit
1 Year Average Return
+17.34%
reiterated a buy rating last month
Copying Andrew Fein's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +17.34% per trade.
---